Hims agrees to limit compounding, ending feud with Novo Nordisknews2026-03-09T14:44:20+00:00March 9th, 2026|Endpoints News|
Bristol Myers says second CELMoD succeeds in Phase 3news2026-03-09T14:33:32+00:00March 9th, 2026|Endpoints News|
Incyte receives CRL over issues at Novo’s Indiana factorynews2026-03-09T13:21:57+00:00March 9th, 2026|Endpoints News|
RNA editing startup Tacit Therapeutics launches with $19M for brain diseasesnews2026-03-09T13:00:55+00:00March 9th, 2026|Endpoints News|
